Results 31 to 40 of about 1,670,952 (313)

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials [PDF]

open access: yes, 2013
Rationale Clinical trial design in interstitial lung diseases (ILDs) has been hampered by lack of consensus on appropriate outcome measures for reliably assessing treatment response.
Antoniou, K   +40 more
core   +1 more source

Regression of murine lung tumors by the let-7 microRNA. [PDF]

open access: yes, 2010
MicroRNAs (miRNAs) have recently emerged as an important new class of cellular regulators that control various cellular processes and are implicated in human diseases, including cancer.
Bader, AG   +10 more
core   +2 more sources

Human epididymis protein 4 (HE4) in benign and malignant diseases [PDF]

open access: yes, 2012
Background: Human epididymis protein 4 (HE4) is described as a useful new biomarker in ovarian cancer. As HE4 is neither tumor nor organ specific, we intensively investigated the occurrence of this protein in female and male patients with various benign ...
Anastasi   +39 more
core   +1 more source

Glutathione s-transferase omega in the lung and sputum supernatants of COPD patients [PDF]

open access: yes, 2015
BACKGROUND: The major contribution to oxidant related lung damage in COPD is from the oxidant/antioxidant imbalance and possibly impaired antioxidant defence. Glutathione (GSH) is one of the most important antioxidants in human lung and lung secretions,
Board, Philip   +7 more
core   +1 more source

Novel folliculin gene mutations in Polish patients with Birt–Hogg–Dubé syndrome

open access: yesOrphanet Journal of Rare Diseases, 2021
Background Birt–Hogg–Dubé syndrome (BHDS) is a rare, autosomal dominant, inherited disease caused by mutations in the folliculin gene (FLCN). The disease is characterised by skin lesions (fibrofolliculomas, trichodiscomas, acrochordons), pulmonary cysts ...
Elżbieta Radzikowska   +3 more
doaj   +1 more source

Indium Lung Disease [PDF]

open access: yesChest, 2012
Reports of pulmonary fibrosis, emphysema, and, more recently, pulmonary alveolar proteinosis (PAP) in indium workers suggested that workplace exposure to indium compounds caused several different lung diseases.To better understand the pathogenesis and natural history of indium lung disease, a detailed, systematic, multidisciplinary analysis of clinical,
Kristin J, Cummings   +15 more
openaire   +2 more sources

Fungal lung disease

open access: yesPaediatric Respiratory Reviews, 2021
Fungal lung disease in the paediatric population occurs with distinct features in the immunocompetent, in immunocompromised patients and in people with cystic fibrosis. Pulmonary mycoses are the least prevalent in immunocompetent children, with the most common diseases being the endemic mycoses and Aspergillomas.
Koltsida, G., Zaoutis, T.
openaire   +3 more sources

Non-Tuberculous Mycobacteria in Respiratory Specimens of Patients with Obstructive Lung Diseases—Colonization or Disease?

open access: yesAntibiotics, 2020
Non-tuberculous mycobacteria (NTM) are increasingly a cause of human respiratory tract colonization and mycobacterial lung disease (NTM-LD), especially in patients with chronic lung diseases.
Monika Szturmowicz   +5 more
doaj   +1 more source

The role of nailfold capillaroscopy in interstitial lung diseases - Can it differentiate idiopathic cases from collagen tissue disease associated interstitial lung diseases? [PDF]

open access: yes, 2015
Introduction: Nailfold capillaroscopy (NFC) is a non-invasive diagnostic test that is mostly used for early diagnosis of collagen tissue diseases (CTDs). We aimed to evaluate whether NFC findings could be a clue for discriminating idiopathic interstitial
Altınışık, Göksel   +4 more
core   +1 more source

A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study

open access: yesBMC Pulmonary Medicine, 2020
Background Pirfenidone is an antifibrotic agent approved for the treatment of idiopathic pulmonary fibrosis (IPF). The drug is available for Polish patients with IPF since 2017. The PolExPIR study aimed to describe the real-world data (RWD) on the Polish
Sebastian Majewski   +25 more
doaj   +1 more source

Home - About - Disclaimer - Privacy